310 related articles for article (PubMed ID: 37866632)
21. Ubiquitin proteasome system in immune regulation and therapeutics.
Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
[TBL] [Abstract][Full Text] [Related]
22. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
23. Expanding PROTACtable genome universe of E3 ligases.
Liu Y; Yang J; Wang T; Luo M; Chen Y; Chen C; Ronai Z; Zhou Y; Ruppin E; Han L
Nat Commun; 2023 Oct; 14(1):6509. PubMed ID: 37845222
[TBL] [Abstract][Full Text] [Related]
24. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
25. Ubiquibodies, synthetic E3 ubiquitin ligases endowed with unnatural substrate specificity for targeted protein silencing.
Portnoff AD; Stephens EA; Varner JD; DeLisa MP
J Biol Chem; 2014 Mar; 289(11):7844-55. PubMed ID: 24474696
[TBL] [Abstract][Full Text] [Related]
26. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
Coll-Martínez B; Delgado A; Crosas B
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
[TBL] [Abstract][Full Text] [Related]
27. E3 ubiquitin-protein ligase TRIM21-mediated lysine capture by UBE2E1 reveals substrate-targeting mode of a ubiquitin-conjugating E2.
Anandapadamanaban M; Kyriakidis NC; Csizmók V; Wallenhammar A; Espinosa AC; Ahlner A; Round AR; Trewhella J; Moche M; Wahren-Herlenius M; Sunnerhagen M
J Biol Chem; 2019 Jul; 294(30):11404-11419. PubMed ID: 31160341
[TBL] [Abstract][Full Text] [Related]
28. ELIOT: A platform to navigate the E3 pocketome and aid the design of new PROTACs.
Palomba T; Baroni M; Cross S; Cruciani G; Siragusa L
Chem Biol Drug Des; 2023 Jan; 101(1):69-86. PubMed ID: 35857806
[TBL] [Abstract][Full Text] [Related]
29. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
30. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
31. TRIM21 inhibits porcine epidemic diarrhea virus proliferation by proteasomal degradation of the nucleocapsid protein.
Wang H; Chen X; Kong N; Jiao Y; Sun D; Dong S; Qin W; Zhai H; Yu L; Zheng H; Tong W; Yu H; Tong G; Shan T
Arch Virol; 2021 Jul; 166(7):1903-1911. PubMed ID: 33900472
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Studies of PROTACs in Hematological Malignancies.
Fuchs O; Bokorova R
Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
[TBL] [Abstract][Full Text] [Related]
33. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
Nalawansha DA; Crews CM
Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
[TBL] [Abstract][Full Text] [Related]
34. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
35. PROTACs: past, present and future.
Li K; Crews CM
Chem Soc Rev; 2022 Jun; 51(12):5214-5236. PubMed ID: 35671157
[TBL] [Abstract][Full Text] [Related]
36. Harnessing nanobodies for target protein degradation through the Affinity-directed PROtein Missile (AdPROM) system.
Carton B; Röth S; Macartney TJ; Sapkota GP
Methods Enzymol; 2023; 681():61-79. PubMed ID: 36764764
[TBL] [Abstract][Full Text] [Related]
37. A label-free quantitative proteomics strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
Burande CF; Heuzé ML; Lamsoul I; Monsarrat B; Uttenweiler-Joseph S; Lutz PG
Mol Cell Proteomics; 2009 Jul; 8(7):1719-27. PubMed ID: 19376791
[TBL] [Abstract][Full Text] [Related]
38. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Singh H; Agrawal DK
Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
[TBL] [Abstract][Full Text] [Related]
39. A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation Applications.
Stacey P; Lithgow H; Lewell X; Konopacka A; Besley S; Green G; Whatling R; Law R; Röth S; Sapkota GP; Smith IED; Burley GA; Harling J; Benowitz AB; Queisser MA; Muelbaier M
SLAS Discov; 2021 Aug; 26(7):885-895. PubMed ID: 34041938
[TBL] [Abstract][Full Text] [Related]
40. Deubiquitinase FAM/USP9X interacts with the E3 ubiquitin ligase SMURF1 protein and protects it from ligase activity-dependent self-degradation.
Xie Y; Avello M; Schirle M; McWhinnie E; Feng Y; Bric-Furlong E; Wilson C; Nathans R; Zhang J; Kirschner MW; Huang SM; Cong F
J Biol Chem; 2013 Feb; 288(5):2976-85. PubMed ID: 23184937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
